AGTR1 signaling contributes to tumor immunity and therapy response in non-small cell lung cancer

Molecular Therapy Oncology 2026 Open access

Read full text
Authors: Tatsuki Ikoma, Keigo Araki, Mai Kitagawa, Natsuno Makihara, Yutaro Nagata, Kazuki Fujii, Yukiko Okuno, Keisuke Kamisako, Yuta Okazaki, Kentaro Nakanishi, Yume Sanada, Kiyori Yoshida
+8 more Kahori Nakahama, Yuki Takeyasu, Utae Katsushima, Yuta Yamanaka, Satoshi Ikeda, Hiroshige Yoshioka, Toshio Shimizu, Takayasu Kurata
DOI: 10.1016/j.omton.2026.201253
Cited by: 1
References: 27

Abstract

= 0.01). AGTR1 is predominantly expressed in CAFs and is suggestive of a correlation with TGF-β-related immunosuppressive features in NSCLC. The combination of ARB with chemo-immunotherapy may enhance therapeutic efficacy through targeting that axis in CAFs, specifically in non-Sq NSCLC patients.

Fields of Study & Subjects

interferon and immune responses Clusterin in disease pathology Cancer Immunotherapy and Biomarkers

Publication details

Journal / source
Molecular Therapy Oncology
Publisher
Elsevier BV
Volume
34
Issue
3
Pages
201253–201253
Publication date
29 May 2026
Language
EN